Sclerostin

Drüeke, Tilman B.; Lafage-Proust, Marie-Hélène

doi:10.2215/cjn.01370211

Cited by 39 publications

(28 citation statements)

References 30 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, b-ALP was not measured in this last study. Moreover, correlation is not causation as underlined by the authors of the editorial [10]. Our results also suggest that sclerostin levels are negatively influenced by high bone turnover in HD patients.…”

Section: Discussionsupporting

confidence: 75%

“…A negative correlation is thus observed between PTH and sclerostin levels [34,38,39,40]. The interaction between PTH and sclerostin is however not fully understood as both intermittent and continuous PTH infusion decreased sclerostin expression [41] whereas only intermittent PTH injection has an anabolic effect on bone [10]. In a HD population, like other authors, we found a negative correlation between PTH and sclerostin concentrations [15,24,26].…”

Section: Discussionsupporting

confidence: 66%

“…Because sclerostin decreases osteoblast activity, its inhibition will lead to an increase in bone formation [9]. If the role of sclerotin in bones is more and more well known, the meaning of sclerostin concentrations in the plasma remains to be precised [10,11]. Nevertheless, discovery of this new pathway in bone formation has opened new perspectives in the field of osteoporosis therapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients

Delanaye¹,

Krzesinski²,

Warling³

et al. 2014

Nephron Clin Pract

View full text Add to dashboard Cite

Background: Sclerostin is a potent inhibitor of bone formation, but the meaning of its serum levels remains undetermined. We evaluated the association between sclerostin levels and clinical or biological data in hemodialyzed patients (HD), notably parathormone (PTH), biomarkers of bone turnover, vascular calcifications and mortality after 2 years. Methods: 164 HD patients were included in this observational study. The calcification score was assessed with the Kauppila method. Patients were followed for 2 years. Results: Median sclerostin levels were significantly (p < 0.0001) higher in HD versus healthy subjects (n = 94) (1,375 vs. 565 pg/ml, respectively). In univariate analysis a significant association (p < 0.05) was found between sclerostin and age, height, dialysis vintage, albumin, troponin, homocysteine, PTH, C-terminal telopeptide of collagen type I, bone-specific alkaline phosphatase and osteoprotegerin, but not with the calcification score. In a multivariate model, the association remained with age, height, dialysis vintage, troponin, homocysteine, phosphate, PTH, but also with vascular calcifications. Association was positive for all variables, except PTH and vascular calcifications. The baseline sclerostin concentration was not different in survivors and non-survivors. Conclusions: We confirm a higher concentration of sclerostin in HD patients, a positive association with age and a negative association with PTH. A positive association with phosphate, homocysteine and troponin calls for additional research. The clinical interest of sclerostin to assess vascular calcifications in HD is limited and no association was found between sclerostin and mortality.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionsupporting

confidence: 66%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients

Delanaye¹,

Krzesinski²,

Warling³

et al. 2014

Nephron Clin Pract

View full text Add to dashboard Cite

show abstract

“…In transgenic mice overexpressing a normal human SOST gene, the bone phenotype observed is an osteopenia; experimentally, blocking sclerostin action by a specific antibody induces more rapid tibial defect repair (5) and an osteoanabolic effect (6). Sclerostin may affect bone metabolism during CKD (7). In patients undergoing maintenance dialysis, sclerostin has been reported to be increased and associated with bone quality impairment (8).…”

Section: Introductionmentioning

confidence: 99%

The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD

Pelletier

Dubourg

Carlier

et al. 2013

Clinical Journal of the American Society of Nephrology

184

138

View full text Add to dashboard Cite

SummaryBackground and objectives Sclerostin, a bone antianabolic peptide involved in osteoporosis, is elevated in patients undergoing maintenance dialysis. However, there are no data for patients with early CKD.Design, setting, participants, & measurements Between January and July 2010, serum sclerostin and GFR (calculated by inulin clearance) were measured in 90 patients with CKD. Fasting blood samples were also drawn for determination of calcium, phosphorus, parathyroid hormone, bone alkaline phosphatase, and 25-OH vitamin D.Results Median GFR was 66.5 (interquartile range, 40.0-88.3) ml/min per 1.73 m 2 . Median sclerostin level was 53.5 (interquartile range, 37.5-77.2) pmol/L, was higher in patients with a GFR ,60 ml/min per 1.73 m 2 , and was highest in those with ESRD. Sclerostin levels were significantly more elevated in men than women (P,0.05). An inverse relationship was found between sclerostin and GFR (r=20.58; P,0.001), and a positive correlation was seen with age (r=0.34; P,0.01) and serum phosphate (r=0.26; P=0.02). In multiple regression analyses, GFR, sex, and serum phosphate were the only variables associated with serum sclerostin (P,0.001). Age lost its relationship with sclerostin level.Conclusions This is the first study reporting higher serum sclerostin levels starting at CKD stage III. GFR, sex, and serum phosphate were the only measures associated with sclerostin level, suggesting that the effect of age reported in the literature might instead be attributable to the altered renal function in the elderly. Correcting the serum phosphorus level may be associated with lower sclerostin levels.

show abstract

“…A esclerostina reduz a proliferação e aumenta a apoptose dos osteoblastos, reduzindo a formação óssea (25). Ela é um potente antagonista da via de sinalização Wnt, vital para o desenvolvimento e renovação de vários tecidos, entre eles o ósseo (26,27 Essas observações demonstram que essa proteína produzida principalmente pelos osteócitos exerce um feedback negativo na diferenciação osteoblástica e no processo de formação óssea.…”

Section: Esclerostinaunclassified

Efeitos da paratireoidectomia na biologia do tecido ósseo de pacientes com doença renal crônica e hiperparatireoidismo secundário

Pires¹

View full text Add to dashboard Cite

DedicatóriaAos meus amados pais, José de Arimatea e Maria de Fátima, que sempre me incentivaram a estudar e são exemplos de ética, companheirismo e dedicação, sendo um porto seguro e fontes de amor, força e crescimento Aos meus irmãos Ary e Julyana e sobrinhos Isabela, Arthur e Eric, tão amados, e que mesmo à distância me dão forças para continuar seguindo em frenteAo meu amado esposo, André, pelo apoio, companhia, paciência e compreensão nessa jornada e por trilhar seus caminhos ao meu lado À minha pequena e amada Sophia, que mesmo antes de nascer, já traz tanta felicidade para toda a família AgradecimentosA Deus, pela vida e por todas as bênçãos, graças e oportunidades concedidas.À minha orientadora, Dra. Vanda Jorgetti, a quem admiro por ser referência como pesquisadora e médica, e, especialmente, como um ser humano inspirador, sempre disposta a ajudar e que nos ensina, através de seu

show abstract

Sclerostin

Cited by 39 publications

References 30 publications

Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients

Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients

The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD

Efeitos da paratireoidectomia na biologia do tecido ósseo de pacientes com doença renal crônica e hiperparatireoidismo secundário

Contact Info

Product

Resources

About